Evaxion Biotech A/S Stock
Evaxion Biotech A/S
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- CEO
- Helen Katrina Tayton-Martin
- Employees
- 46
- Market cap
- $18 M
- IPO
- 05/02/2021
- Web
- evaxion.ai
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer…
Evaxion Biotech A/S stock: price history
1D
+1.1%
1W
-7.8%
1M
-6.6%
6M
-36.4%
YTD
-40.7%
1Y
-70.5%
2Y
-79.1%
5Y
-99.3%
10Y
–
Next earnings date
Next earnings date
19/11/2026 (in 33 days)
Volatility around earnings
~73% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Evaxion Biotech A/S
Analyst assessment of Evaxion Biotech A/S
PRICE TARGET LOW
US$9.00
CONSENSUS
US$11.67
MEDIAN
US$10.00
PRICE TARGET HIGH
US$16.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 24/04/2026
Evaxion Biotech A/S stock metrics
P/E
-0.46
P/B
0.12
EV/EBITDA
-1.11
RETURN ON EQUITY
-39.1%
NET MARGIN
0.0%
DEBT/EQUITY
0.75
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.8%
FLOAT SHARES
5,102,445
AVG. DAILY VOLUME (30D)
46,579
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Evaxion Biotech A/S stock
What does Evaxion Biotech A/S do?
Evaxion Biotech A/S is a company in the Healthcare sector, Biotechnology industry, headquartered in Denmark.
The CEO is Helen Katrina Tayton-Martin, the company employs around 46 people.
The IPO was on 05/02/2021; the stock trades on NASDAQ under the ticker EVAX.
What do analysts say about Evaxion Biotech A/S stock?
4 analysts rate the stock, the consensus is Buy (as of 24/04/2026).
The average price target is US$11.67, ranging from US$9.00 to US$16.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Evaxion Biotech A/S report next?
The next earnings date is 19/11/2026.
Around past earnings, price swings were roughly 73% stronger than usual.
Does Evaxion Biotech A/S pay a dividend?
No, Evaxion Biotech A/S currently does not pay a dividend.
Which stocks are comparable to Evaxion Biotech A/S?
Comparable stocks include Genmab A/S, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Evaxion Biotech A/S stock analyzed?
Clicking "Analyze stock" lets five strategies assess Evaxion Biotech A/S against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.